NASDAQ : BFRIW
-$0.01 (-18.95%)
NASDAQ
Hermann Luebbert
Drug Manufacturers - Specialty & Generic
Healthcare
BFRIW
92
US
USD
1.27
1.20
1.09
0.58
0.00
$41.7M
0.32
2.10
-1.50
-0.80
-$0.9
-$10.54M
-25.66%
-25.60%
-476.72%
-44.72%
-0.97
-0.03
-0.03
2/5
0 Analysts
%
-5.80
2/9
$2.24M
$24.79M
$18.72M
-$4.96M
$15.23M
0.35
-1.52
1.20
-476.72%
-62.07%
-87.85%
-67.39%
-85 days
| Name | Title |
|---|---|
| Jon Lyons | Vice President of Scientific & Medical Affairs |
| Samantha Widdicombe | Senior Vice President of Sales & Strategic Accounts |
| George Jones | Chief Commercial Officer |
| Erica F. Gates | VP of Finance & Principal Accounting Officer |
| Hermann Luebbert | Chief Executive Officer, President & Chairman |
| Daniel Hakansson | Senior Corporate Counsel |
| Eugene Frederick Leffler | Chief Financial Officer |
No votes yet today — be the first to share your view!
About Biofrontera Inc. (NASDAQ:BFRIW) Stock
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts. ...
2026-05-21 09:15:00
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Frequently Asked Questions
What is the current Biofrontera Inc. (BFRIW) stock price?
Biofrontera Inc.(NASDAQ:BFRIW) stock price is $0.0231 in the last trading session. During the trading session, BFRIW stock reached the peak price of $0.0971 while $0.0231 was the lowest point it dropped to. The percentage change in BFRIW stock occurred in the recent session was --18.95% while the dollar amount for the price change in BFRIW stock was -$0.01.
BFRIW's industry and sector of operation?
The NASDAQ listed BFRIW is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
Who are the executives of BFRIW?
Jon Lyons
| Vice President of Scientific & Medical Affairs
Samantha Widdicombe
| Senior Vice President of Sales & Strategic Accounts
George Jones
| Chief Commercial Officer
Erica F. Gates
| VP of Finance & Principal Accounting Officer
Hermann Luebbert
| Chief Executive Officer, President & Chairman
How many employees does BFRIW have?
Number of BFRIW employees currently stands at 92. BFRIW operates from 120 Presidential Way, Woburn, MA 01801, US.
Link for BFRIW official website?
Official Website of BFRIW is: https://www.biofrontera-us.com
How do I contact BFRIW?
BFRIW could be contacted at phone #781-245-1325 and can also be accessed through its website. BFRIW operates from 120 Presidential Way, Woburn, MA 01801, US.
How many shares of BFRIW are traded daily?
The average number of BFRIW shares traded daily for last 3 months was 5.7K.
What is the market cap of BFRIW currently?
The market value of BFRIW currently stands at $8.9M with its latest stock price at $0.0231